



05/20/05

IPW / 1614

CASE ON/4-32419A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV 48366918045 Express Mail Label Number	MAY 19, 2005 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
DENT ET AL.

INTERNATIONAL APPLICATION NO: PCT/IB03/01418

FILED: 4 APRIL 2003

U.S. APPLICATION NO: 10/510,531

35 USC §371 DATE: 30 MARCH 2005

FOR: COMBINATION OF GLIVEC (STI571) WITH A CYCLIN-  
DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN  
THE TREATMENT OF CANCER

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
Oona A. Jackson  
Attorney for Applicants  
Reg. No. 48,152

Date: 5/19/05

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32419A  
APPLICATION NO.  
10/510,531  
APPLICANT  
DENT ET AL.  
FILING DATE  
MARCH 30, 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2002/0147197	10/10/02	Newman et al.	514	235.8	03/20/02
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 01/26467	04/19/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Fabbro et al., "Protein Kinases as Targets for Anticancer Agents: from Inhibitors to Useful Drugs", <i>Pharmacol Thera</i> , Vol. 93, Nos. 2-3, pp. 79-98 (2002).
	AS	Workman, "The Impact of Genomic and Proteomic Technologies on the Development of New Cancer Drugs", <i>Ann Oncol</i> , Vol. 13, No. 12, Suppl. 4, pp. 115-124 (2002).
	AT	Yanovich, Hall and Gewirtz, "Characterization of a K562 Multidrug-resistant Cell Line", <i>Cancer Res</i> , Vol. 49, No. 16, pp. 4499-4501 (1989).

EXAMINER /Marcos Sznajdman/ DATE CONSIDERED 01/24/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
ON/4-32419A  
APPLICATION NO.  
10/510,531  
APPLICANT  
DENT ET AL.  
FILING DATE  
MARCH 30, 2005

Group

EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

DA	* Yu et al., "The Cyclin Dependent Kinase Inhibitor Flavopiridol Interacts Synergistically with the BCR/ABL Kinase Inhibitor ST1571 to Induce Mitochondrial Damage and Apoptosis in BCR/ABL+ Human Leukemia Cells (K562 and Lama-84)", <i>Blood</i> , Vol. 98, No. 11, p. 146a (2001).
DB	Yu et al., "Pharmacologic Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase/Mitogen-activated Protein Kinase Inhibitors Interact Synergistically with ST1571 to Induce Apoptosis in BCR/ABL-expressing Human Leukemia Cells", <i>Cancer Res</i> , Vol. 62, No. 1, pp. 188-199 (2002).
DC	Yu, Krystal, Dent and Grant, "Flavopiridol Potentiates ST1571-induced Mitochondrial Damage and Apoptosis in BCR-ABL-positive Human Leukemia Cells", <i>Clin Cancer Res</i> , Vol. 8, No. 9, pp. 2976-2984 (2002).
DD	
DE	
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

/Marcos Sznaidman/

DATE CONSIDERED

01/24/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./